D espite significant advances in our ability to detect and treat atrial fibrillation (AF), less than half of high embolic risk patients receive oral anticoagulants (OACs). 1 The main cause of this problem is the known association between OACs and intracranial hemorrhage (ICH), the latter being the most lethal and disabling condition known to humans, among the relatively common medical emergencies. The last decade saw the development and more recently the Food and Drug Administration (FDA) approval of an endovascular left atrial appendage closure (LAAC) procedure, namely WATCHMAN (Boston Scientific, Plymouth, MN; Figure 1 ), as a second-line treatment for stroke and systemic embolism prevention in nonvalvular AF (NVAF) without the need for lifelong anticoagulation. Other endovascular and surgical LAAC devices and procedures are currently being developed and tested in clinical trials. The other important advance has been the development of imaging markers that can help stratify the risk of ICH in individual patients. Current AF management guidelines recommend choosing the antithrombotic therapy based on shared decision-making approaches, after discussion of the absolute and relative risks of stroke and bleeding, taking into account the patient's values and preferences.
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2 Table 1 and Figures 2 and 3 provide an overview of conditions that are associated with a relatively high ICH risk. In patients with NVAF and any of these high ICH risk conditions, LAAC might be considered for ischemic and hemorrhagic stroke prevention, taking into account the safety and efficacy of the device compared with OAC.
The current article will present (1) problems related to lifelong anticoagulation in patients at high ICH risk, (2) data on use of the nonpharmacological stroke prevention measures with an emphasis on LAAC, and (3) data on stratification of ICH risk to help select neurological patients who might benefit from LAAC.
Problems With Lifelong Anticoagulation in Patients at High ICH Risk
Warfarin is an established treatment to prevent ischemic stroke in NVAF reducing overall stroke risk by 64%. 3 A direct thrombin inhibitor (dabigatran) and 3 activated factor X inhibitors (rivaroxaban, apixaban, and edoxaban) collectively called as direct oral anticoagulants (DOAC) proved to have advantages compared with warfarin in NVAF: (1) noninferiority for overall stroke prevention, (2) significantly decreased risk of ICH in a general NVAF population, (3) ease of use, once or twice daily intake without the need for blood draws, and (4) lower risk of drug and food interactions. 4 Relative disadvantages include risk of gastrointestinal side effects/hemorrhage, higher cost, safety concerns in older adults with reduced renal function, availability and efficacy of reversal strategies, and finally relatively poor patient compliance as a result of these problems.
Despite their established benefits in a general NVAF population, 2 major concerns further limit the widespread use of OACs: (1) OACs increase the risk of ICH, and (2) OACrelated ICHs are even more deadly than non-OAC-related ICHs. The reported incidence of OAC-related ICH is 7-to 10-fold higher than in patients who are not receiving OAC. 5 On the basis of meta-analyses of randomized controlled trials (RCTs) in NVAF, warfarin increased ICH risk 3-fold when compared with placebo and 2-fold when compared with aspirin. 3, 6 Finally, a recent network meta-analysis of OAC for stroke prevention in AF showed a 5-fold increase in ICH risk for warfarin against placebo and 2-to 3-fold increased risk for the currently approved doses of DOACs. 7 Despite the fact that ischemic strokes are more common than ICH, ICHs are overall associated with 3× higher casefatality rates. 8 OAC-related ICHs have poorer outcomes than non-OAC-related ICH (mortality 52% versus 25.8%, respectively), presumably because of the faster and more severe early hematoma growth as a result of OAC-related coagulopathy. 9 Available data show that patients with DOAC-related ICHs have poor outcomes, similar to warfarin ICH based on phase 3 trials comparing DOACs to warfarin (Table 2) . [10] [11] [12] [13] Large multicenter observational studies confirmed these results, showing that two thirds of DOAC-related ICH patients were dead or severely disabled at 3 months. 14, 15 Varying overall poor results were also reported for different outcome measures in warfarin ICH and DOAC-related ICH. 15, 16 The clinical efficacy of the reversal agents for DOACs has not been addressed and unlikely to be studied in an RCT for ICH. The FDA-approved idarucizumab and any reversal agent that might be approved in the future will probably be used in a hope to limit ICH expansion, similar to reversal agents in warfarin ICH.
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No patient with past history of ICH was enrolled to any of the phase III AF trials (including AVERROES [Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment]), and current guidelines recommend avoidance of long-term warfarin use in NVAF patients who had warfarin-associated lobar ICH. 17 Understanding hemorrhagic risks and nonpharmacological treatments is important to discuss potential alternatives with patients who have increased ICH risk, while using the OACs as the established first-line treatments in the majority of AF patients who do not necessarily have high ICH risk at baseline.
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Nonpharmacological Stroke Prevention
Measures in AF
LAA as the Site of Thrombus Formation in NVAF
The LAA, an embryonic remnant of the original left atrium, is a long, tubular, trabeculated structure, in continuity with the left atrial cavity (Figure 1 ). Since late 1940s, it was recognized that LAA's unique anatomy can result in stagnant blood flow in AF predisposing to in situ thrombus formation. 19 Its shape varies among individuals and the fact that more-complex internal characteristics such as cauliflower morphology put even low CHA 2 DS 2 -VASc score AF patients at significantly higher embolic risk than the simpler chicken wing or windsock morphologies also supports its hypothesized role in AF-related thrombus formation. 20 Evaluating the exact site of intracardiac thrombus formation in AF using data from larger transesophageal echocardiography, autopsy and operation series have been performed since 1960s. A landmark 1996 review of these studies showed that 254 of 446 (57%) patients with rheumatic AF had thrombi localized to, or present in, the LAA, whereas 201 of 222 (91%) nonrheumatic AF-related thrombi were isolated to, or originated in, the LAA. 21 On the basis of these data, surgical obliteration of the LAA was thought to eliminate an important nidus of thrombus formation which in turn might reduce thromboembolic complications, especially in patients with NVAF. However, the concern was the difficulty to demonstrate benefit in a randomized trial because of the relatively low incidence of embolic complications in general NVAF populations and also the invasive nature of open thoracic surgeries. The past 2 decades brought the validation of scoring systems that stratify embolic risk in NVAF such as CHADS 2 and CHA 2 DS 2 -VASc. Building on the advances in catheter-based cardiac interventions, endovascular devices and procedures were also developed to close the LAA without the need for invasive open surgeries. The main categories consist of internal occlusion and external ligation/clipping/amputation. The most commonly used LAA closure methods are demonstrated in Figure 1 , and the scientific data supporting their use are reviewed below.
Nonsurgical LAA Closure
Endovascular WATCHMAN Procedure
The WATCHMAN device is a self-expanding umbrella-shaped filter about the size of a quarter that has nitinol structure covered by a porous polyethylene terephthalate membrane on the proximal surface ( Figure 1 ). The implantation is performed through femoral venous access, and the delivery system is advanced into the left atrium via septal puncture. The device is designed to be permanently implanted at or slightly distal to the ostium of the LAA to prevent embolization by isolating LAA from the circulation. It takes about 45 days for an endothelial layer to grow over the device after which the anticoagulant is typically stopped if a transesophageal echocardiography also shows no connection or a jet smaller than 5 mm in diameter between LAA and left atrium (definition of good LAA seal). Figure 1 shows the device and the basics of its implantation.
The PROTECT AF study (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) compared the efficacy and safety of percutaneous closure of LAA to warfarin in NVAF patients with at least 1 risk factor (previous stroke or transient ischemic attack, congestive heart failure, diabetes mellitus, hypertension, or age ≥75). 22 The primary composite end point of stroke, cardiovascular death, These conditions define nonvalvular atrial fibrillation (NVAF) patients who have an appropriate rationale to seek a nonpharmacological alternative to lifelong oral anticoagulation, shedding light into FDA approval wording for WATCHMAN device. For these NVAF patients, it is ideal to hold shared decision-making meetings to discuss the management options that include anticoagulation, left atrial appendage closure, and others. AIS indicates acute ischemic stroke; CAA, cerebral amyloid angiopathy; CMB, cerebral microbleeds; ICH, intracranial hemorrhage; IPH, intraparenchymal hemorrhage; IVH, intraventricular hemorrhage; MRI, magnetic resonance imaging; SAH, subarachnoid hemorrhage; SDH, subdural hemorrhage; and; TIA, transient ischemic attack. and systemic embolism occurred in 3.0 per 100 patient-years in the WATCHMAN group and 4.9 per 100 patient-years in the warfarin group (rate ratio [RR], 0.62; 95% confidence interval, 0.35-1.25), proving noninferiority of the intervention. Primary safety events were more frequent in the WATCHMAN group mostly related to the performance of this new procedure (7.4 versus 4.4 per 100 patient-years). 22 At 3.8 years mean followup, the primary event rate for WATCHMAN was 2.3 versus 3.8 per 100 patient-years for warfarin, showing again noninferiority and reaching the prespecified criteria for superiority of the intervention against long-term anticoagulation. 23 There was an 85% reduction in hemorrhagic strokes in the WATCHMAN arm (RR, 0.15; 95% confidence interval, 0.03-0.49), an issue particularly relevant to the focus of this review.
During the early assessments, FDA requested more data to prove the procedural safety and long-term efficacy so the continued access protocol and another RCT, the PREVAIL trial (Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy), were launched. 24 PREVAIL included an NVAF group at higher embolic risk than PROTECT AF (mean CHA 2 DS 2 -VASc 4 versus 3.5). 25 Both of these studies showed better procedural safety results for the intervention than PROTECT AF. 26, 27 The continued access protocol registry also showed better primary outcomes when compared with expected event rates in this single-arm observational study. 28 The primary combined efficacy end points were similar and expectedly low for both WATCHMAN (0.064) and warfarin (0.063), yielding a mean 18-month rate ratio of 1.07 (95% confidence interval, 0.57-1.89) in PREVAIL. 27 The upper bound of 1.89 of this wide credible interval did not fulfill the prespecified noninferiority margin of 1.75. The extremely well-performing warfarin arm of PREVAIL (only 1 ischemic stroke out of 138 randomized to anticoagulation) corresponding to 0.3 per 100 patientyears contributed to this result. This rate is far superior to that observed in any warfarin group of any clinical trial, including the recent DOAC studies and PROTECT AF, all showing ischemic stroke rates >1 per 100 patient-years. 4, 13 WATCHMAN achieved noninferiority for the second coprimary efficacy end point (stroke or SE >7 days postrandomization) in PREVAIL. WATCHMAN received FDA approval for stroke prevention in NVAF on March 13, 2015. After a thorough review, the Centers for Medicare & Medicaid Services decided to cover WATCHMAN procedure as a second-line therapy to OACs with the following conditions. LAAC with WATCHMAN can be considered in patients with NVAF and a relatively high embolic risk score (CHADS 2 ≥2 or CHA 2 DS 2 -VASc ≥3) suitable for short-term warfarin use, in whom there is an appropriate rationale to seek a nonpharmacological alternative to OACs, taking into account the safety and efficacy of the device compared with OAC. Centers for Medicare & Medicaid Services approval also mandates a formal shared decision-making interaction with an independent noninterventional physician using an evidence-based decision tool. Such encounter must be documented in the medical record, and the patient should remain under the care of a cohesive, multidisciplinary team of medical professionals both preoperatively and postoperatively.
A recent meta-analysis of all data from RCTs and continued access protocol registry (2406 patients, mean follow-up of 2.69 years) showed that WATCHMAN significantly reduced hemorrhagic stroke (hazard ratio [HR], 0.22; P=0.004), cardiovascular/unexplained death (HR, 0.48; P=0.006), and nonprocedural bleeding (HR, 0.51; P=0.006) while showing a trend for higher ischemic stroke rates (HR, 1.95; P=0.05) when compared with warfarin. All-cause stroke or systemic embolism was similar between WATCHMAN and warfarin (1.75 versus 1.87 events/100 patient-years; P=0.94). 25 Postmarketing real-world data from the United States (n=3822) and Europe (n=1021) showed satisfactory successful deployment rates (95.6% and 98.5%) and decreased procedural complication rates when compared with RCTs: pericardial effusion/tamponade (1% and 0.3%), device embolization (0.24% and 0.2%), procedural stroke (0.08% and 0.1%), and death within 7 days (0.08% and 0.3%). 29, 30 The possibilities of procedural failure (inability to implant the device), potential complications, and long-term outcomes should be discussed with each patient considered for LAAC, using device-specific data.
WATCHMAN implantation is typically done by cardiac electrophysiologists and interventional cardiologists using an advanced echocardiographic method (transesophageal echocardiography or intracardiac ECHO) in addition to fluoroscopy, under local or general anesthesia. The presence of a learning curve was obvious in the early studies, and it is reasonable to think that skilled and experienced staff are more likely to obtain better procedural results. It is nevertheless important to note that the increasing proportion of new operators (71%) who performed 50% of the consecutive procedures included in postapproval US experience study did not alter the high procedural success rates (95.6%). Finally, it is important to be familiar with the antithrombotic regimen used after WATCHMAN: warfarin (target international normalized ratio, 2-3) and aspirin 81 mg/d are used until good LAA seal is shown on a transesophageal echocardiography, typically performed 45 days after implantation. When good LAA seal is confirmed, warfarin is discontinued and the patient is switched to a combination of aspirin 81 to 325 mg/d and clopidogrel 75 mg/d. After 6 months, clopidogrel is discontinued and patients are kept on aspirin 81 to 325 mg/d. ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) showed acceptable safety of using 6 months of treatment with a thienopyridine antiplatelet agent (clopidogrel or ticlopidine) after WATCHMAN implantation and lifelong aspirin in patients deemed to have an absolute contraindication for warfarin. 31 Short-term use of DOACs immediately after the procedure is done nowadays at some centers with equivalent results to warfarin, although this is still not the FDA-approved standard of care.
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Other Endovascular or Hybrid Procedures for LAA Occlusion Multiple devices are being developed to occlude the LAA using endovascular approaches, all conceptually and procedurally similar to WATCHMAN, such as AMPLATZER/Amulet (St. Jude Medical, St. Paul, MN), Wavecrest occluder device (Coherex Medical Inc, Salt Lake City, UT), LAmbre (Lifetech Scientific Corp, Shenzhen, China), and others. These latter devices have not been tested for stroke prevention so evidence for clinical efficacy is lacking and they are not FDA approved. AMPLATZER cardiac plug and its newer generation device AMULET received Conformité Européene mark approval in Europe for LAAC, and AMULET is currently being tested for stroke prevention in a pivotal trial (Figure 1) . A multicenter retrospective registry of AMPLATZER cardiac plug showed 97.3% procedural success and 5% periprocedural major adverse events in a total of 1047 patients included. 33 The LARIAT suture delivery system (SentreHeart, Redwood City, CA) uses a hybrid epicardial and transcatheter endocardial approach to ligate the LAA from the outside of pericardium using a pretied suture. 34 The device was approved by FDA for soft tissue approximation but not for LAAC or stroke prevention in AF. Although the idea of suturing LAA from outside without leaving any foreign material inside the heart is appealing, the procedure is more invasive than the pure endovascular LAAC methods and a high rate of major procedural complications was reported. 35 Consequently, the FDA issued an alert for healthcare providers and patients, of reports of patient deaths and other serious adverse events associated with the use of the LARIAT Suture Delivery Device for LAAC on July 13, 2015.
Surgical LAA Closure
LAA has been a target for surgical closure using different techniques since 1940s, performed in conjunction with mitral valve, coronary artery bypass grafting, and AF surgeries. There are only limited and contradictory data about the safety and effectiveness of surgical LAAC due in part to problems identifying the patients who might benefit from this intervention among surgical populations with multiple comorbidities. Incomplete surgical LAA closure remains a major concern especially when less effective methods such as suturing/stapling are used with reported failure rates up to 57%. 36, 37 Incomplete surgical closure is associated with a higher risk of thromboembolism. 38 The AtriClip LAA Occlusion System (AtriCure, Inc, West Chester, OH; Figure 1 ) proved to be a safe epicardial LAA exclusion approach in open cardiac surgery patients with reported successful complete closure rates over 95%. 39 This device has been FDA approved for LAA exclusion during open cardiac surgery since 2009. As an epicardial clipping method with very high LAA exclusion rates that does not leave any foreign body inside the heart, AtriClip might become an important approach to stop OACs in AF patients at particularly high ICH risk if further data support its clinical efficacy in stroke prevention.
Catheter and Surgical AF Ablation
Catheter and surgical ablation have developed as established approaches in AF patients when a rhythm control strategy is needed or chosen. 40 The definition of success is highly variable but ablation seems to present better results than medical treatment for both decreasing the AF load and controlling symptoms, especially for paroxysmal AF. Although the idea of discontinuing anticoagulation is conceptually attractive in patients without return of AF months to years after ablation, there currently is no evidence from RCTs that stopping OAC is safe at any time point after ablation. There is only one observational study that showed lower stroke rates in AF patients who had ablation when compared with AF without ablation, but these results would not support routine discontinuation of OAC after ablation; the efficacy of such an approach cannot be tested in an observational study. 41 The current AF ablation guidelines clearly mention that a desire to discontinue anticoagulation is not an appropriate indication to perform AF ablation. 40 
Stratifying ICH Risk
Understanding the hemorrhagic risk with or without long-term anticoagulation is as important as determining embolic risk to select the optimal stroke prevention measures in AF. 42 Table 1 summarizes neurological conditions with a relatively high ICH risk. Figures 2 and 3 demonstrate imaging examples of the most common cerebral pathologies associated with high ICH risk. It is important to remember that hemorrhagic risk scores such as HAS-BLED, ORBIT, and ATRIA were developed for a general population without particular ICH risk so they are not relevant to this discussion. ICH is an umbrella term that encompasses bleeding inside different intracranial compartments, each associated with different risk factors and recurrent bleeding risk.
Intraparenchymal Hemorrhage
Intraparenchymal hemorrhage (IPH), also called hemorrhagic stroke or intracerebral hemorrhage, constitutes 8% to 18% of all strokes. 42 Most IPHs in older adults are caused by 2 types of cerebral small-vessel diseases (cSVD): (1) cerebral amyloid angiopathy (CAA), and (2) hypertensive deep IPH. Cerebral microbleeds (CMBs), a relatively common pathology seen on T2* magnetic resonance imaging of elderly with or without IPH, and cortical superficial siderosis (cSS) can also suggest the presence of these hemorrhage-prone cerebrovascular pathologies and help stratify IPH risk (Figures 2 and 3) .
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January 2018 CAA causes a significant risk of brain hemorrhage but also some vascular dysfunction and resultant ischemic damage. 43 CAA is an important cause of warfarin-related IPH and the cause of most primary (nontraumatic) lobar IPHs in older adults. 44 Lobar CMBs and cSS are key markers of CAA when alternative pathologies are ruled out (Figure 2) . The average annual risk of recurrent IPH in patients who had a CAArelated lobar IPH is 9% to 10%. 42, 45, 46 The presence and extent of cSS proved to be the most important radiological marker of IPH risk in CAA, the annual recurrence risk ranging from 5% if no cSS to 26.9% if disseminated/multifocal cSS present. 47 The carriers of the Apolipoprotein E e2 or e4 allele have a higher recurrence risk. 42 Patients who present with neurological symptoms and a brain magnetic resonance imaging showing multiple strictly cortical/lobar CMBs without IPH have a 5% annual risk of first-time IPH (Figure 3) . 45 Warfarin anticoagulation and older age were independent predictors of first-time symptomatic IPH among such patients, so long-term anticoagulation is not a benign approach even for this CMBonly population.
Hypertensive (HTN) deep-seated IPH is the most common cause of primary IPH worldwide (Figure 3 ). Hypertensive cSVD causes CMBs in deep brain locations and a mixed location pattern of ICH/CMBs (both deep and lobar). Patients who survive a deep HTN-IPH have an annual 1.6% to 2% recurrence risk, whereas the risk of recurrence is higher (5.1%) for survivors of mixed location ICH/CMBs (Figure 3 ).
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Other ICH Types
It is difficult to predict the risk of fall-related ICH (traumatic parenchymal hemorrhage, subdural hemorrhage (SDH), or epidural hemorrhage) but if such concern is prohibitive of longterm OAC in an NVAF patient, it might be reasonable to consider LAAC. As aspirin used after LAAC in long-term might increase risk for trauma-related ICH, a careful risk-benefit assessment and discussion with patient/family is important.
Chronic SDH is an increasingly frequent condition seen in older adults, related in part to brain atrophy. Chronic SDH is found to be closely related to anticoagulation, with 21% of chronic SDH occurring on Warfarin and use of warfarin increasing the risk by 42.5-folds. 48 A large meta-analysis including 34 829 chronic SDH patients reported 11 per 100 patient-years recurrence rate so lifelong OAC use is a difficult consideration in these patients.
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Identifying High-Risk Patients Before the ICH
The ultimate goal of the preventive medicine is to identify patients at high risk for serious acute events such as ICH before they occur and take appropriate precautions to minimize the risk. Such individualized medicine approaches in the field of ICH are now possible thanks to a better understanding of a large array of neuroimaging markers of cSVDs that signal a high baseline ICH risk, which could further increase if long-term anticoagulants were used. There currently are no RCT data on risks and benefits of OACs and LAAC for stroke prevention in NVAF patients who have the following risk factors. While such data are awaited, an open discussion of these management options with the patient can individualize the treatment thereby improving the patient's adherence.
Cerebral Microbleeds
Microbleeds are present in one fourth of patients with acute ischemic stroke and transient ischemic attacks. 50 Both the presence of any CMB (pooled RR, 6.3) and their increased numbers (RR, 4.6 for 1 CMB; RR, 14.1 for ≥5 CMBs) are significant predictors of future IPH risk. 50 CMBs are also found in one fifth of otherwise healthy people over 45, and the risk of symptomatic first-time IPH is higher in these adults (HR adjusted for age/sex, 5.68). 51 Overall, CMBs even without IPH are absolute markers of high future IPH risk regardless of the clinical presentation. CMBs also constitute a risk factor for both warfarin-and DOAC-related ICH. Distinct CMBs were found in 79.2% of warfarin ICH and 80% of DOAC-related ICHs when compared with 22.9% of patients using warfarin who never had ICH. 52, 53 White Matter Disease, Cognitive, and Gait Problems Another well-known imaging marker of cSVD that was associated with increased hemorrhagic risk is white matter disease also termed leukoaraiosis (Figure 2 ). White matter disease is caused by ischemic consequences of the common cSVDs of older adults, namely CAA and hypertensive SVD, the same conditions that result in CMBs, IPH, and cognitive and gait problems. 54 Leukoaraiosis on computed tomography was associated with higher ICH risk in older adults free of stroke taking warfarin in an RCT. 55 Presence of moderateto-severe white matter disease, cognitive, and gait problems present valid concerns in patients considered for lifelong OAC use.
Conclusions
Nonpharmacological approaches including the FDAapproved WATCHMAN LAAC procedure that obviates the need for lifelong anticoagulation have significantly expanded our options to help patients with AF and concomitant high ICH risk. It is important for the practitioner to be familiar with these procedures and stratification strategies for ICH risk to provide the best possible care to AF patients. The stroke neurologist has the ultimate responsibility to put the patient's preferences at the center stage using shared decision-making approaches while working closely with the cardiologist and interventional physicians when needed.
